Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1084 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Abbott net sales up in Q2

Abbott‘s net earnings were $1.94bn, compared to $1.29bn for the same period in the prior year. The company’s operating earnings was $1.77bn for the second quarter ended 30

Teva Canada upgrades Ontario plants

The expansion of Stouffville plant and equipment deployment will allow Teva Canada to produce one billion more tablets of prescription based generic medicines per year. Further, the expansion

Pfizer to take over Icagen

Currently, Pfizer has 11% ownership of Icagen’s fully diluted shares. Pfizer expects to purchase the remaining 8.3m shares at $6 per share. In 2007, Pfizer and Icagen joined

Astrazeneca ACS drug gets FDA nod

Brilinta is indicated to reduce unstable angina, non-ST-elevation myocardial infarction or ST-elevation myocardial infarction in patients with ACS. The FDA approval was given on the basis of the

AHM appoints new CEO

AHM is a supplier of speaker program and commercial compliance management solutions for the pharmaceutical industry. Prior to joining AHM, Burgess was the president and CEO of Healthland.

SuperGen acquires Astex

Following the acquisition, Astex has become a wholly owned subsidiary of SuperGen. SuperGen plans to re-brand Astex Therapeutics as Astex Pharmaceuticals in the third quarter of 2011. The